Total Payments
$414.12
2024 Payments
$174.91
Companies
10
Transactions
20
Medicare Patients
3,584
Medicare Billing
$579,701
Payment Breakdown by Category
Food & Beverage$357.16 (86.2%)
Education$56.96 (13.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $357.16 | 18 | 86.2% |
| Education | $56.96 | 2 | 13.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $88.38 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $61.00 | 3 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $56.96 | 2 | $0 (2022) |
| AIMMUNE THERAPEUTICS, INC. | $43.47 | 2 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $38.47 | 2 | $0 (2024) |
| Theratechnologies Inc. | $35.63 | 2 | $0 (2018) |
| Shionogi Inc | $32.74 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $24.40 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $20.34 | 1 | $0 (2018) |
| Allergan, Inc. | $12.73 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $174.91 | 9 | ViiV Healthcare Company ($49.75) |
| 2023 | $50.52 | 2 | Merck Sharp & Dohme LLC ($31.68) |
| 2022 | $28.48 | 1 | Janssen Pharmaceuticals, Inc ($28.48) |
| 2021 | $44.73 | 2 | Janssen Pharmaceuticals, Inc ($28.48) |
| 2019 | $12.73 | 1 | Allergan, Inc. ($12.73) |
| 2018 | $82.72 | 4 | Janssen Biotech, Inc. ($24.40) |
| 2017 | $20.03 | 1 | Theratechnologies Inc. ($20.03) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: HIV | ||||||
| 09/16/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/23/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: GI | ||||||
| 06/14/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: HIV | ||||||
| 05/17/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: HIV | ||||||
| 05/10/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: GI | ||||||
| 04/12/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO, DIFICID | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/15/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/01/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/10/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $31.68 | General |
| 08/08/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/25/2022 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $28.48 | General |
| 12/17/2021 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $28.48 | General |
| 03/23/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: HIV | ||||||
| 04/26/2019 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/08/2018 | Janssen Biotech, Inc. | Symtuza (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/04/2018 | Theratechnologies Inc. | EGRIFTA (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: HIV | ||||||
| 05/10/2018 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: HIV | ||||||
| 03/21/2018 | ViiV Healthcare Company | JULUCA (Drug) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: HIV | ||||||
| 09/13/2017 | Theratechnologies Inc. | EGRIFTA (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 720 | 1,379 | $189,223 | $113,321 |
| 2022 | 4 | 971 | 1,486 | $252,559 | $155,111 |
| 2021 | 5 | 955 | 1,974 | $255,776 | $158,053 |
| 2020 | 3 | 938 | 2,541 | $246,060 | $153,215 |
Total Patients
3,584
Total Services
7,380
Medicare Billing
$579,701
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 311 | 350 | $87,500 | $47,860 | 54.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 186 | 697 | $69,700 | $43,566 | 62.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 69 | 94 | $11,750 | $8,824 | 75.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 69 | 133 | $6,916 | $5,187 | 75.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 73 | $8,197 | $4,827 | 58.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 32 | $5,160 | $3,058 | 59.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 620 | 704 | $176,000 | $110,585 | 62.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 221 | 579 | $57,900 | $32,691 | 56.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 82 | 111 | $13,875 | $9,001 | 64.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 48 | 92 | $4,784 | $2,833 | 59.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 460 | 534 | $133,500 | $86,154 | 64.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 285 | 931 | $93,100 | $54,075 | 58.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 173 | 465 | $24,180 | $14,362 | 59.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 26 | $3,250 | $2,116 | 65.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 18 | $1,746 | $1,347 | 77.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 366 | 404 | $101,000 | $66,340 | 65.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 292 | 1,430 | $74,360 | $45,617 | 61.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 280 | 707 | $70,700 | $41,258 | 58.4% |
About Dr. David Rowles, MD
Dr. David Rowles, MD is a Infectious Disease healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205805785.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Rowles, MD has received a total of $414.12 in payments from pharmaceutical and medical device companies, with $174.91 received in 2024. These payments were reported across 20 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($357.16).
As a Medicare-enrolled provider, Rowles has provided services to 3,584 Medicare beneficiaries, totaling 7,380 services with total Medicare billing of $579,701. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Richmond, VA
- Active Since 03/16/2006
- Last Updated 07/31/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1205805785
Products in Payments
- CABENUVA (Biological) $51.13
- VOWST (Biological) $43.47
- REBYOTA (Biological) $38.47
- EGRIFTA (Drug) $35.63
- Fetroja (Drug) $32.74
- PIFELTRO (Drug) $29.32
- Symtuza (Drug) $24.40
- JULUCA (Drug) $22.38
- Biktarvy (Drug) $20.34
- DOVATO (Drug) $14.87
- AVYCAZ (Drug) $12.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Richmond
Mr. Barnett Gibbs, M.d., Facc, M.D., FACC
Infectious Disease — Payments: $5,301
Infectious Disease $5,301
Dr. Benjamin Bluen, M.d, M.D
Infectious Disease — Payments: $1,619
Infectious Disease $1,619
Dr. George Vail, M.d, M.D
Infectious Disease — Payments: $1,351
Infectious Disease $1,351
Julie Boatman, Do, DO
Infectious Disease — Payments: $706.52
Infectious Disease $706.52
Julie Reznicek, D.o, D.O
Infectious Disease — Payments: $625.00
Infectious Disease $625.00
Nicole Vissichelli, Md, MD
Infectious Disease — Payments: $468.08
Infectious Disease $468.08